Boston Scientific has entered into an agreement to acquire SoniVie Ltd., a medical device company that developed the TIVUS Intravascular Ultrasound System. This investigational technology is designed to treat hypertension by denervating nerves surrounding blood vessels, specifically through renal artery denervation. The acquisition expands Boston Scientific’s interventional cardiology portfolio with an ultrasound-based alternative to existing renal denervation therapies.

Hypertension is a leading risk factor for cardiovascular disease, and existing treatments, including medications and lifestyle changes, are often insufficient. The TIVUS system uses ultrasound energy to penetrate tissue more deeply than radiofrequency-based methods, potentially enabling faster procedures with effective nerve ablation.

Boston Scientific currently holds a 10% equity stake in SoniVie. The acquisition involves an upfront payment of approximately $360 million for the remaining 90%, with up to $180 million in additional payments contingent on regulatory milestones. The transaction is expected to close in the first half of 2025. The company anticipates a slight dilutive effect on adjusted earnings in 2025, offset by internal cost efficiencies.

The TIVUS system remains an investigational device and is not yet approved for commercial use. Boston Scientific continues to expand its portfolio of innovative cardiovascular treatments through strategic acquisitions.

Boston Scientific Corporation has announced the completion of a €1.5 billion public offering of senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The company had previously announced the pricing of these senior notes on February 21, 2025.

Additionally, Boston Scientific recently reported strong financial results for the fourth quarter and full year 2024, with CEO Mike Mahoney describing it as "one of the best years in the history of the company." The company continues to expand its cardiovascular portfolio, with acquisitions such as Bolt Medical, Inc., and Intera Oncology, Inc., aimed at strengthening its interventional cardiology and oncology offerings.

Boston Scientific will also participate in TD Cowen’s 45th Annual Health Care Conference in March 2025.

Boston Scientific Corporation has announced the pricing of €1.5 billion in senior notes through its wholly owned finance subsidiary, American Medical Systems Europe B.V. The issuance includes €850 million of 3.000% notes due 2031 and €650 million of 3.250% notes due 2034. The offering is expected to close on February 26, 2025, subject to customary conditions. The proceeds, combined with cash on hand, will be used to repay AMS Europe's 0.750% senior notes due March 8, 2025, and for general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.

Boston Scientific Corporation reported strong financial results for both the fourth quarter and full year of 2024. The company posted net sales of $4.561 billion for the fourth quarter, reflecting a 22.4% increase on a reported basis and a 19.5% rise on an organic basis, surpassing its guidance range. For the full year, net sales totaled $16.747 billion, marking a 17.6% increase compared to the previous year. The company also saw a rise in net income, with GAAP net income for the fourth quarter reaching $566 million, or $0.38 per share, up from $504 million or $0.34 per share in 2023. Adjusted EPS for the quarter was $0.70, higher than the previous year's $0.55.

The growth was driven by significant performance in the Cardiovascular segment, which saw a 28.8% increase in reported sales, and strong results from the United States, which contributed a 30.7% increase in reported sales. Boston Scientific also highlighted several key developments, including the approval of the FARAPULSE Pulsed Field Ablation System, positive clinical trial results for the WATCHMAN FLX Left Atrial Appendage Closure Device, and multiple strategic acquisitions. The company acquired Axonics, Inc. and Cortex, Inc., expanding its product offerings, while also announcing agreements to acquire Bolt Medical and Intera Oncology, further solidifying its position in the medical device industry.